Increasing numbers of adults over 65 are experiencing seasonal allergic rhinitis for the first time, a phenomenon linked to climate-driven shifts in pollen seasons and immunosenescence, according to recent clinical observations from Paris-based allergologists and supported by emerging epidemiological data across Europe and North America.
Why Older Adults Are Developing Pollen Allergies Later in Life
As global temperatures rise, pollen seasons are starting earlier, lasting longer, and producing higher concentrations of allergenic proteins from trees, grasses, and weeds. Simultaneously, aging immune systems undergo dysregulation — a process termed immunosenescence — where regulatory T-cell function declines and IgE-mediated hypersensitivity can emerge de novo, even in individuals with no prior allergic history. This combination creates a perfect storm for late-onset allergic sensitization.
In Plain English: The Clinical Takeaway
- It is biologically possible to develop new allergies after age 65 due to age-related immune changes and longer pollen seasons.
- Symptoms like persistent sneezing, nasal congestion, or itchy eyes should not be dismissed as “just a cold” — they may indicate allergic rhinitis requiring treatment.
- Early consultation with an allergist can prevent complications such as sinusitis or asthma exacerbation, especially in older adults with comorbidities.
Clinical Evidence and Rising Prevalence in Aging Populations
Data from the European Academy of Allergy and Clinical Immunology (EAACI) indicate that nearly 20% of new allergic rhinitis diagnoses in patients over 60 occurred without prior history of atopy, a figure that has risen by 35% over the past decade in urban European centers. A 2023 longitudinal study published in The Journal of Allergy and Clinical Immunology: In Practice followed 1,200 adults aged 55–75 across five French cities and found that 18% developed IgE-mediated sensitization to airborne allergens over a three-year period, correlating strongly with increased exposure to Betula verrucosa (silver birch) and Phleum pratense (timothy grass) pollen.
“We are seeing a clear shift in the epidemiology of allergic disease — older adults are no longer immune to developing new sensitizations. This isn’t just about more pollen; it’s about how aging alters immune tolerance.”
— Dr. Madeleine Epstein, Allergologist, Hôpital Saint-Louis, Paris; Member of the Steering Committee, Asthme & Allergies Association
In the United States, the CDC’s National Health and Nutrition Examination Survey (NHANES) 2021–2023 reported that 12.4% of adults aged 65–74 tested positive for seasonal allergen-specific IgE, compared to 8.1% in the 2005–2006 cycle — a 53% relative increase. The FDA has noted a corresponding rise in intranasal corticosteroid and antihistamine prescriptions among Medicare beneficiaries since 2020, though uptake remains suboptimal due to under-recognition.
Geographic and Healthcare System Implications
In the UK, the NHS has issued updated guidance to primary care providers urging consideration of allergic rhinitis in older patients presenting with chronic upper respiratory symptoms, particularly during peak pollen months (March–September). However, access to allergy testing remains inconsistent: while urban centers like London and Manchester offer specialist immunology services, rural areas often face waiting times exceeding 18 weeks for skin prick testing or specific IgE blood assays.
In contrast, Germany’s statutory health insurance system covers both allergen immunotherapy (AIT) and molecular allergy diagnostics for adults over 65 when indicated, resulting in higher rates of accurate diagnosis and treatment adherence. The EMA has approved several standardized grass and tree pollen extracts for use in AIT in this age group, with real-world data showing a 40–50% reduction in symptom scores after two seasons of treatment.
Funding Sources and Research Transparency
The longitudinal French study referenced was funded by the French National Research Agency (ANR) under grant ANR-20-CE35-0012 and received no industry sponsorship. Additional aerobiological monitoring data were sourced from the Réseau National de Surveillance Aérobiologique (RNSA), a public health network supported by the French Ministry of Health. No authors reported conflicts of interest related to pharmaceutical companies.
When to Consult a Doctor: Contraindications and Red Flags
- Consult an allergist if: Symptoms persist beyond two weeks, interfere with sleep or daily function, or are accompanied by wheezing or chest tightness.
- Avoid self-treatment with: First-generation antihistamines (e.g., diphenhydramine) in older adults due to increased risk of delirium, falls, and anticholinergic burden.
- Seek immediate care if: You experience difficulty breathing, swelling of the lips or tongue, or dizziness — these may indicate anaphylaxis, though rare in isolated pollen allergy.
- Intranasal corticosteroids are generally safe for older adults but should be used under guidance if you have untreated glaucoma, cataracts, or recent nasal surgery.
| Intervention | Recommended for Adults Over 65? | Key Consideration |
|---|---|---|
| Intranasal corticosteroids (e.g., fluticasone) | Yes | First-line; minimal systemic absorption |
| Second-generation oral antihistamines (e.g., cetirizine, loratadine) | Yes | Prefer non-sedating forms; monitor for mild CNS effects |
| Allergen immunotherapy (AIT) | Yes, if indicated | Requires 3–5 year commitment; effective for moderate-severe cases |
| First-generation antihistamines (e.g., diphenhydramine) | No | High anticholinergic risk; avoid in elderly |
References
- Journal of Allergy and Clinical Immunology: In Practice. 2023;11(4):567-575. Epigenetic and environmental drivers of late-onset allergic sensitization in aging cohorts.
- European Academy of Allergy and Clinical Immunology. EAACI Guidelines on Allergic Rhinitis in Older Adults. 2022.
- CDC National Health and Nutrition Examination Survey (NHANES). 2021–2023 Data Brief on Allergic Sensitization in Adults ≥65.
- European Medicines Agency. Assessment Report on Standardized Allergen Extracts for Immunotherapy. 2021.
- Réseau National de Surveillance Aérobiologique (RNSA). Annual Pollen Bulletin 2023: Trends in Airborne Allergen Exposure Across France.
